396 related articles for article (PubMed ID: 25666802)
1. Lipid nanocarriers (LNC) and their applications in ocular drug delivery.
Puglia C; Offerta A; Carbone C; Bonina F; Pignatello R; Puglisi G
Curr Med Chem; 2015; 22(13):1589-602. PubMed ID: 25666802
[TBL] [Abstract][Full Text] [Related]
2. Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective.
Qamar Z; Qizilbash FF; Iqubal MK; Ali A; Narang JK; Ali J; Baboota S
Recent Pat Drug Deliv Formul; 2019; 13(4):246-254. PubMed ID: 31884933
[TBL] [Abstract][Full Text] [Related]
3. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers.
Abdel-Mottaleb MM; Neumann D; Lamprecht A
Eur J Pharm Biopharm; 2011 Sep; 79(1):36-42. PubMed ID: 21558002
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.
Uner M
Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531
[TBL] [Abstract][Full Text] [Related]
5. Application of lipid nanoparticles to ocular drug delivery.
Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
[TBL] [Abstract][Full Text] [Related]
6. Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration.
Fonseca-Santos B; Silva PB; Rigon RB; Sato MR; Chorilli M
Curr Med Chem; 2020; 27(22):3623-3656. PubMed ID: 31232233
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.
Souto EB; Doktorovova S; Gonzalez-Mira E; Egea MA; Garcia ML
Curr Eye Res; 2010 Jul; 35(7):537-52. PubMed ID: 20597640
[TBL] [Abstract][Full Text] [Related]
8. SLN, NLC, LDC: state of the art in drug and active delivery.
Attama AA
Recent Pat Drug Deliv Formul; 2011 Sep; 5(3):178-87. PubMed ID: 21834777
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics.
Pathak K; Keshri L; Shah M
Crit Rev Ther Drug Carrier Syst; 2011; 28(4):357-93. PubMed ID: 21967401
[TBL] [Abstract][Full Text] [Related]
10. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers.
Shidhaye SS; Vaidya R; Sutar S; Patwardhan A; Kadam VJ
Curr Drug Deliv; 2008 Oct; 5(4):324-31. PubMed ID: 18855604
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():70-75. PubMed ID: 27789358
[TBL] [Abstract][Full Text] [Related]
12. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
Teixeira MC; Carbone C; Souto EB
Prog Lipid Res; 2017 Oct; 68():1-11. PubMed ID: 28778472
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers system: recent advances in drug delivery.
Iqbal MA; Md S; Sahni JK; Baboota S; Dang S; Ali J
J Drug Target; 2012 Dec; 20(10):813-30. PubMed ID: 22931500
[TBL] [Abstract][Full Text] [Related]
14. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():58-69. PubMed ID: 27789359
[TBL] [Abstract][Full Text] [Related]
16. Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.
Shree D; Patra CN; Sahoo BM
Pharm Nanotechnol; 2024; 12(3):229-250. PubMed ID: 37587812
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers.
Sah AK; Suresh PK
Recent Pat Nanotechnol; 2015; 9(2):94-105. PubMed ID: 27009124
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity.
Pignatello R; Carbone C; Puglia C; Offerta A; Bonina FP; Puglisi G
Ther Deliv; 2015; 6(11):1297-318. PubMed ID: 26608630
[TBL] [Abstract][Full Text] [Related]
19. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
Srinivasarao DA; Lohiya G; Katti DS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
[TBL] [Abstract][Full Text] [Related]
20. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.
Tan G; Li J; Song Y; Yu Y; Liu D; Pan W
Acta Biomater; 2019 Nov; 99():350-362. PubMed ID: 31449929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
